Nathan Schnaper Intern Program in Translational Cancer Research - NSIP

Nathan Schnaper Intern Program in Translational Cancer Research - NSIP The NSIP is an innovative internship program that allows undergraduate students to conduct research at the University of Maryland Greenebaum Cancer Center.

The Nathan Schnaper Intern Program in Translational Cancer Research (NSIP) at the Marlene and Stewart Greenebaum Cancer Center (UMGCC) was started over 20 years ago by the Baltimore Cancer Research Program, predecessor to the current UMGCC. Over 200 interns have participated in the NSIP to date, most of whom have matriculated to medical or graduate school. The program was initially funded by local

philanthropy and pharmaceutical/biotechnology contributions. An endowment was later established to honor Dr. Nathan Schnaper, a highly regarded UMGCC psychiatrist and a longtime advocate of the internship. The program allows undergraduate students to be mentored by UMGCC faculty for 10 weeks, during which they will conduct research in multiple areas of investigation including drug resistance, signal transduction, programmed cell death, molecular pharmacology, and carcinogenesis. The interns are also exposed to diverse areas of cancer research during weekly discussion sections with the mentors, and have opportunities for clinical shadowing with our faculty.

Very exciting findings on glioblastoma by one of our NSIP labs!
12/11/2025

Very exciting findings on glioblastoma by one of our NSIP labs!

Glioblastoma is the deadliest form of brain cancer. A new study is bringing hope that it could be survivable.
The publication in The Lancet Oncology, led by Dr. Graeme Woodworth, Professor and Chair of Neurosurgery at the University of Maryland School of Medicine and Neurosurgeon-In-Chief at UMMC, shows promising results.
The study is the first to find a potential survival benefit to adding focused ultrasound to standard chemotherapy.
The key advancement is getting treatment directly into the brain. The blood–brain barrier normally blocks toxins but it also blocks most therapies. Focused ultrasound temporarily opens this barrier, which allows chemotherapy to enter the brain and target the dangerous cancer cells that remain after standard treatment. The barrier then closes again.
The goal is to use focused ultrasound to treat tumors more effectively, monitor for signs of regrowth, and re-treat patients when needed. This form of treatment is currently only available in clinical trials and work still needs to be done to confirm these results in larger studies, but Dr. Woodworth says this is an exciting step forward.

Read the full story in The Baltimore Banner: https://www.thebanner.com/community/public-health/focused-ultrasound-study-glioblastoma-brain-cancer-LAGEPSTQ2RBPHJGX7VG7PFNXQM/


Address

655 W. Baltimore Street, BRB 9th Floor, University Of Maryland Greenebaum Cancer Center
Baltimore, MD
21201

Telephone

+14103282345

Website

Alerts

Be the first to know and let us send you an email when Nathan Schnaper Intern Program in Translational Cancer Research - NSIP posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The University

Send a message to Nathan Schnaper Intern Program in Translational Cancer Research - NSIP:

Shortcuts

Share

Category